文献速递神经肌肉病

微量二硝基苯酚在肌萎缩侧索硬化小鼠中保留运动和肌肉功能并带来功能恢复期

Micro-Doses of DNP Preserve Motor and Muscle Function with a Period of Functional Recovery in Amyotrophic Lateral Sclerosis Mice.
PubMed 文献 · Ann Neurol · 2024-11-18

研究在hSOD1G93A肌萎缩侧索硬化小鼠中评估微量线粒体解偶联剂2,4-二硝基苯酚(DNP)的疗效。从症状前或发病起每日口服灌胃0.5-1.0 mg/kg DNP至18周龄,DNP延迟发病、改善运动协调和肌肉性能、保留肌肉收缩功能与神经肌肉接头形态及肌肉支配、减少炎症和蛋白氧化;发病后开始治疗的小鼠在治疗数周后出现以20 cm/s奔跑能力的恢复期。作者认为微量DNP在最佳剂量和干预时机下可能成为ALS患者的新型治疗选择并存在恢复可能。

要点

  • 微量DNP(0.5-1.0 mg/kg)每日口服灌胃可延迟hSOD1G93A小鼠发病并改善运动协调与肌肉性能。
  • DNP保留肌肉收缩功能、神经肌肉接头形态和肌肉支配,并减少炎症与蛋白氧化。
  • 发病后开始DNP治疗的小鼠在数周后出现20 cm/s奔跑能力的恢复期。

核心结论

  • 结果强烈支持微量DNP在最佳剂量和干预时机下可能作为肌萎缩侧索硬化患者的新型治疗并存在恢复可能。

研究设计与样本

  • hSOD1G93A小鼠从症状前阶段或发病起每日口服灌胃0.5-1.0 mg/kg DNP直至18周龄。
  • 6至18周龄期间每周或每两周进行纵向行为学研究。
  • 进行趾长伸肌原位肌肉收缩测量以评估DNP治疗后hSOD1G93A小鼠收缩力和运动单位数量的保留。
  • 使用免疫染色评估肌肉支配和炎症标志物,并检测蛋白氧化程度和Akt通路激活。

主要发现

  • DNP延迟发病并改善hSOD1G93A小鼠在体运动协调和肌肉性能。
  • DNP在18周龄时保留hSOD1G93A小鼠肌肉收缩功能、神经肌肉接头形态和肌肉支配,并减少炎症和蛋白氧化。
  • 发病时开始DNP治疗的症状性hSOD1G93A小鼠在治疗开始数周后出现以20 cm/s奔跑能力的恢复期,为使用小分子逆转疾病表型的首次观察。

临床怎么用

  • 作者认为微量DNP在最佳剂量和干预时机下可能作为肌萎缩侧索硬化患者的新型治疗并存在恢复可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Mitochondrial dysfunction is one of the earliest pathological events observed in amyotrophic lateral sclerosis (ALS). The aim of this study is to evaluate the therapeutic efficacy of 2,4-dinitrophenol (DNP), a mild mitochondrial uncoupler, in an ALS mouse model to provide preclinical proof-of-concept evidence of using DNP as a potential therapeutic drug for ALS. METHODS: hSOD1G93A mice were treated with 0.5-1.0 mg/kg DNP through daily oral gavage from presymptomatic stage or disease onset until 18 weeks old. Longitudinal behavioral studies were performed weekly or biweekly from 6 to 18 weeks old. In situ muscle contraction measurements in extensor digitorum longus muscles were conducted to evaluate the preservation of contractile force and motor unit numbers in hSOD1G93A mice following DNP treatment. Muscle innervation and inflammatory markers were assessed using immunostaining. Extent of protein oxidation and activation of Akt pathway were also examined. RESULTS: DNP delayed disease onset; improved motor coordination and muscle performance in vivo; preserved muscle contractile function, neuromuscular junction morphology, and muscle innervation; and reduced inflammation and protein oxidation at 18 weeks old in hSOD1G93A mice. Strikingly, symptomatic hSOD1G93A mice exhibited a period of recovery in running ability at 20 cm/s several weeks after 2,4-dinitrophenol treatment started at disease onset, offering the first observation in disease phenotype reversal using a small molecule. INTERPRETATION: Our results strongly support that micro-dose DNP may be used as a potential novel treatment for ALS patients, with a possibility for recovery, when used at optimal doses and time of intervention. ANN NEUROL 2025;97:542-557.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Zhong R, Dionela DLA, Kim NH, et al. Micro-Doses of DNP Preserve Motor and Muscle Function with a Period of Functional Recovery in Amyotrophic Lateral Sclerosis Mice. Ann Neurol. 2024. PMID: 39552508. doi:10.1002/ana.27140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。